Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 with QS-21 Extension Study in Alzheimer's Disease
NCT00955409Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2009
- Primary completion
- Dec 2013
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of vanutide cridificar in Alzheimer's disease (AD), sponsored by Pfizer. Started Nov 2009; status: completed.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00955409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955409.